These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34230073)
41. Feasibility of a Scale-down Production of [ Migliari S; Sammartano A; Scarlattei M; Baldari G; Janota B; Bonadonna RC; Ruffini L Curr Radiopharm; 2022; 15(1):63-75. PubMed ID: 33687908 [TBL] [Abstract][Full Text] [Related]
42. Development of an Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111 [TBL] [Abstract][Full Text] [Related]
43. Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4. Mi B; Xu Y; Pan D; Wang L; Yang R; Yu C; Wan W; Wu Y; Yang M Biochem Biophys Res Commun; 2016 Feb; 471(1):47-51. PubMed ID: 26850848 [TBL] [Abstract][Full Text] [Related]
44. Structure-Activity Relationships and Pharmacokinetics of Iikuni S; Ohara T; Watanabe H; Ono M Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958 [TBL] [Abstract][Full Text] [Related]
45. Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Körner M; Christ E; Wild D; Reubi JC Front Endocrinol (Lausanne); 2012; 3():158. PubMed ID: 23230431 [TBL] [Abstract][Full Text] [Related]
46. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET. Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750 [TBL] [Abstract][Full Text] [Related]
50. Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor-Positive Lesions. Boss M; Bos D; Frielink C; Sandker G; Bronkhorst P; van Lith SAM; Brom M; Buitinga M; Gotthardt M J Nucl Med; 2020 Nov; 61(11):1588-1593. PubMed ID: 32385165 [TBL] [Abstract][Full Text] [Related]
51. Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. Brom M; Joosten L; Oyen WJ; Gotthardt M; Boerman OC Contrast Media Mol Imaging; 2012; 7(2):160-6. PubMed ID: 22434628 [TBL] [Abstract][Full Text] [Related]
52. Molecular Imaging to the Surgeons Rescue: Gallium-68 DOTA-Exendin-4 Positron Emission Tomography-Computed Tomography in Pre-operative Localization of Insulinomas. Pallavi UN; Malasani V; Sen I; Thakral P; Dureja S; Pant V; Gaikwad VS; Sabharwal A Indian J Nucl Med; 2019; 34(1):14-18. PubMed ID: 30713372 [TBL] [Abstract][Full Text] [Related]
53. 68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia. Parihar AS; Vadi SK; Kumar R; Mittal BR; Singh H; Bal A; Walia R; Shukla J; Sinha SK Clin Nucl Med; 2018 Aug; 43(8):e285-e286. PubMed ID: 29877881 [TBL] [Abstract][Full Text] [Related]
54. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321 [TBL] [Abstract][Full Text] [Related]
56. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals. Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208 [TBL] [Abstract][Full Text] [Related]
57. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting. Kondo N; Oishi A; Hirata M; Temma T Ann Nucl Med; 2021 Jan; 35(1):83-91. PubMed ID: 33067731 [TBL] [Abstract][Full Text] [Related]